August 12, 2022 05:55 AM EDTUpdated 06:45 AM

As Covid program advances, Enanta's new CMO says it's not 'limited to antivirals'; With all eyes on Gilead-partnered cancer drugs, Arcus brings medical chief on board

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Kyle LaHucik

Senior Reporter

Expect some pipeline adjustments at Enanta Pharmaceuticals in the coming years, because new CMO Scott Rottinghaus thinks the antiviral biotech can …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

As Covid program advances, Enanta's new CMO says it's not 'limited to antivirals'; With all eyes on Gilead-partnered cancer drugs, Arcus brings medical chief on board

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

NewAmsterdam aces Phase 3 trial, but investors are skeptical

Post-Hoc: RFK vs. Vivek, and the future of US drug policy

FDA updates label of 33-year-old cancer drug with new dose and warning

When generative AI meets the FDA: First digital health adcomm kicks off discussion

Pfizer partners with two more Flagship biotechs on obesity, cancer

Are programs with compounded GLP-1s safe for your population?

As Covid pro­gram ad­vances, Enan­ta's new CMO says it's not 'lim­it­ed to an­tivi­ral­s'; With all eyes on Gilead-part­nered can­cer drugs, Ar­cus brings med­ical chief on board

Copy Chief

Editor

Senior Reporter

Sign up to read this article for free.

As Covid program advances, Enanta's new CMO says it's not 'limited to antivirals'; With all eyes on Gilead-partnered cancer drugs, Arcus brings medical chief on board